ProMIS Licenses Brain Shuttle Reporting 65-Fold Delivery Gain
ProMIS Neurosciences announced a license agreement with Ossianix on Tuesday, November 17, 2026 for TXP1, a brain-selective shuttling technology aimed at transferrin receptor 1. In preclinical studies reported by Ossianix, including work in non-human primates, TXP1 raised delivery of a therapeutic antibody to the brain by more than 65-fold. Those are animal and laboratory results, not human data.
Edited and fact-checked by Stephen Sprague
TXP1's 65-fold figure comes from preclinical work, and no patient has received a TXP1-carried antibody. ProMIS's first-generation PMN310 continues in its Phase 1b trial on its own track, and the shuttle's first human test is the event that decides what the license is worth.
In Cambridge, Massachusetts, on Tuesday, ProMIS Neurosciences signed for a delivery vehicle its Alzheimer's antibody doesn't yet have.
The blood-brain barrier keeps most large molecules out of the brain, and antibodies are large molecules. A shuttle solves that by hitching the antibody to a receptor that ferries cargo across. TXP1 targets transferrin receptor 1, a receptor that normally moves iron into cells.
TXP1 is built on a VNAR scaffold, a single-domain antibody fragment far smaller than a conventional antibody, and Ossianix has deimmunized it to reduce the chance the immune system reacts to it. In preclinical studies reported by Ossianix, including studies in non-human primates, TXP1 increased delivery of a therapeutic antibody to the brain by more than 65-fold.
Ossianix also reported no accumulation in the liver, spleen, lung, kidney, bone marrow, heart or muscle, and prolonged exposure in the brain. The company says TXP1 binds without competing with transferrin itself, and that it had minimal impact on reticulocyte levels, a side effect reported with some other transferrin receptor approaches. Each of those claims comes from preclinical work, and none has been tested in a patient.
The antibody at the center of the deal is PMN310. It's a humanized monoclonal antibody designed to bind toxic oligomers, the soluble clumps of amyloid protein, while avoiding the plaques themselves. ProMIS argues that selectivity could reduce the brain swelling and bleeding risks, known as ARIA, that come with plaque-binding Alzheimer's drugs.
PMN310 holds Fast Track designation from the Food and Drug Administration, granted in July 2025. It's being tested in PRECISE-AD, a randomized, double-blind, placebo-controlled Phase 1b study in people with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease. For those families, the practical question is dosing. A working shuttle could support a second-generation version given as an injection under the skin rather than an intravenous infusion in a clinic.
ProMIS was plain that the license doesn't change the current program. President and chief executive Neil Warma said the company's ongoing work with PMN310 is unaffected and that it remains committed to advancing the antibody as an intravenous and subcutaneous product, subject to upcoming data. TXP1 is a lifecycle project behind it, not a replacement.
The license reaches past Alzheimer's. ProMIS holds options to apply TXP1 to PMN442, its antibody against alpha-synuclein, a protein implicated in Parkinson's disease and dementia with Lewy bodies, and to PMN267, its antibody against TDP-43, implicated in ALS and frontotemporal dementia.
Money terms are partly undisclosed. Ossianix receives an upfront payment and is eligible for development, regulatory and commercial milestone payments plus royalties on global net sales, and the release doesn't state the amounts. ProMIS says it will fund its short-term obligations from existing cash and doesn't expect the agreement to change its previously disclosed cash runway through 2027.
What the deal doesn't contain is a human result. Transferrin receptor shuttles have a long record of strong animal numbers, and the field's history says primate delivery gains don't transfer to patients at the same size. The next evidence that matters is a first clinical study of a TXP1-carried antibody, and neither company has announced a date for one.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.